Avandia suspected in deaths.
Type 2 diabetes drug rosiglitazone (Avandia) accounted for 1,354 patient deaths in 2009, more than any other prescription drug, according to a report from the Institute for Safe Medication Practices. However, the institute blamed publicity about the drug's cardiovascular safety risks in part for the large number of fatalities reported to the FDA. "The manufacturer, GlaxoSmithKline, told us earlier that it believed many of the adverse drug event reports for rosiglitazone were associated with possible lawsuits against the company," the report said. The institute excluded reports it knew were associated with legal claims but said it couldn't rule out the bad publicity as the reason for increased reporting of cardiovascular events and deaths associated with rosiglitazone in 2009.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||POLICY & PRACTICE|
|Publication:||Internal Medicine News|
|Article Type:||Brief article|
|Date:||Jul 1, 2010|
|Previous Article:||Men less likely to get care.|
|Next Article:||Implementing health reform: closing the doughnut hole.|